TG Therapeutics Inc (NASDAQ: TGTX) on Monday, plunged -9.44% from the previous trading day, before settling in for the closing price of $26.90. Within the past 52 weeks, TGTX’s price has moved between $9.81 and $26.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2506.46% over the past five years. The company achieved an average annual earnings per share of -41.98%. With a float of $137.98 million, this company’s outstanding shares have now reached $151.42 million.
Let’s look at the performance matrix of the company that is accounted for 264 employees. In terms of profitability, gross margin is 92.69%, operating margin of 29.37%, and the pretax margin is 27.62%.
TG Therapeutics Inc (TGTX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of TG Therapeutics Inc is 10.88%, while institutional ownership is 59.93%. The most recent insider transaction that took place on Jun 20 ’24, was worth 275,791. In this transaction Director of this company sold 16,348 shares at a rate of $16.87, taking the stock ownership to the 105,195 shares. Before that another transaction happened on Jun 17 ’24, when Company’s Director sold 9,585 for $16.39, making the entire transaction worth $157,098. This insider now owns 99,293 shares in total.
TG Therapeutics Inc (TGTX) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.73 earnings per share (EPS) for the period topping the consensus outlook (set at 0.12) by 0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -41.98% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
TG Therapeutics Inc (TGTX) is currently performing well based on its current performance indicators. A quick ratio of 2.83 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.29. Likewise, its price to free cash flow for the trailing twelve months is 59.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit 0.09 in the next quarter and is forecasted to reach 0.95 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
TG Therapeutics Inc (NASDAQ: TGTX) saw its 5-day average volume 4.81 million, a positive change from its year-to-date volume of 3.65 million. As of the previous 9 days, the stock’s Stochastic %D was 68.56%. Additionally, its Average True Range was 1.41.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 75.60%, which indicates a significant increase from 39.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.88% in the past 14 days, which was higher than the 60.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.52, while its 200-day Moving Average is $18.69. Nevertheless, the first resistance level for the watch stands at $25.30 in the near term. At $26.24, the stock is likely to face the second major resistance level. The third major resistance level sits at $27.43. If the price goes on to break the first support level at $23.17, it is likely to go to the next support level at $21.98. The third support level lies at $21.04 if the price breaches the second support level.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
Market capitalization of the company is 4.05 billion based on 154,823K outstanding shares. Right now, sales total 233,660 K and income totals 12,670 K. The company made 73,470 K in profit during its latest quarter, and 6,880 K in sales during its previous quarter.
